1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Tolosa P, García-Fructuoso I, Pascual T, Martínez-Sáez O, Cejalvo JM, Servitja S, Fernández Abad M, Benitez Fuentes JD, Brasó-Maristany F, Sanfeliu E, Lema L, Ruano Y, Parrilla L, Roncero AM, Cobos MÁ, Díaz I, Centelles López KA, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

    BREAST CANCER RESEARCH AND TREATMENT . 216(2): .

    [doi:10.1007/s10549-026-07931-7]

  • Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D.

    Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

    Journal for ImmunoTherapy of Cancer . 14(2): .

    [doi:10.1136/jitc-2025-013713]

  • Chong AS, Roca C, Morales-Sánchez P, Dorca E, Barea V, Ruz-Caracuel I, Valderrabano P, Rovira C, Jou C, Bouron-Dal Soglio D, Chernock RD, Torrezan GT, Pusztaszeri M, Cameselle-Teijeiro JM, Matias-Guiu X, Alvarez CV, Salvador H, Wasserman JD, Leandro-García LJ, Foulkes WD, Andrés-León E, Casano-Sancho P, Rivera B.

    Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions.

    Jci Insight . 11(3): .

    [doi:10.1172/jci.insight.198338]

  • González-Martínez S, Palacios J, Carretero-Barrio I, Fernández-Lanza V, Cortés-Salgado A, Román J, Matias-Guiu X, Gatius S, Cortés J, Pérez-Mies B.

    Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.

    JOURNAL OF PATHOLOGY . 268(2): 227-242.

    [doi:10.1002/path.70003]

  • Casas Gállego VR, Perez Muñoz I, Sanz Pascual MDC, Gonzalez Lizan F, Reguero Callejas ME, Delgado Martínez I.

    Extra-axial chordoma in the distal fibula and the importance of ankle reconstruction.

    WORLD JOURNAL OF SURGICAL ONCOLOGY . 24(1): .

    [doi:10.1186/s12957-025-04187-1]

  • Borrego MR, López-Bravo DP, Vila MM, Pérez-García JM, Fernández M, Tormo SB, García-Saenz JÁ, Lema L, Garau I, Cortez P, Torres AA, Conejo EA, Calvo I, Ferrer N, Blancas I, Amillano K, Santasusagna S, Benderra MA, Alcalá-López D, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J.

    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study

    EUROPEAN JOURNAL OF CANCER . 233: 116161-116161.

    [doi:10.1016/j.ejca.2025.116161]

  • Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthélémy P, Voog E, Cutuli HJ, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK.

    Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

    LANCET ONCOLOGY . 27(1): 68-78.

    [doi:10.1016/S1470-2045(25)00566-2]

  • Ruz-Caracuel I.

    Recent advances in pituitary tumors following the 2022 WHO classification.

    ENDOCRINOLOGIA DIABETES Y NUTRICION . 73(1): 501747-501747.

    [doi:10.1016/j.endien.2026.501747]

  • Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Liedke PER, Carroll D, Khan S, Rugo HS, Xu B, Bardia A.

    Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study.

    Annals of oncology : official journal of the European Society for Medical Oncology . : .

    [doi:10.1016/j.annonc.2025.12.017]

  • Martín M, Guerrero-Zotano AL, Pérez-López ME, Ruiz-Borrego M, Martinez Jañez N, Chacón JI, Gil-Gil M, Andrés R, Bermejo B, Sánchez-Rovira P, Del Barco S, Ponce JJ, Fernandez I, Martínez de Dueñas E, Hinojo-Gonzále C, González M, García-Garre E, Hernando B, de la Haba-Rodriguez J, Álvarez IM, González-Santiago S, Garcia-Saenz JA, Santaballa A, Casas M, Bezares S, Caballero R, Rojo F, Alba E.

    Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

    CLINICAL CANCER RESEARCH . 32(5): 850-858.

    [doi:10.1158/1078-0432.CCR-25-2435]

  • Ruz-Caracuel I, Rosell A, Geryková L, Gama JM, Alonso-Gordoa T, Rodríguez-Villena A, Almeida R, Rosas M, Martínez-Hernández R, Martins MJ, Ryska A, Eloy C, Palacios J.

    Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma

    ENDOCRINE PATHOLOGY . 36(1): 49-49.

    [doi:10.1007/s12022-025-09894-9]

  • Biagetti B, Cardona-Arias A, Torre EM, Aulinas A, Ruz-Caracuel I, Centeno RG, González L, Echarri AI, Rodríguez MDM, Paja M, Guerrero-Pérez F, Castaño JP, García MDO, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabéu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Rojas-Marcos PM, Recio-Córdova JM, Lozano-Aida C, Roca QA, Aviles MD, Mezquita EL, Argueso MF, Molero IG, Alberoa I, Idrobo C, Achote E, Martínez-Sáez E, Marazuela M, Puig-Domingo M, Hanzu F, Araujo-Castro M.

    Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study

    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION . 48(12): 2857-2867. Nº de citas: 2

    [doi:10.1007/s40618-025-02674-6]

  • Martínez-Hernández R, Méndez-García FF, Serrano-Somavilla A, Sacristán-Gómez P, Sánchez de la Blanca N, Sampedro-Núñez M, Navas-Moreno V, Sebastián-Valles F, Fernández-Alen JA, Biagetti B, Ruz-Caracuel I, Araujo-Castro M, Puig-Domingo M, Marazuela M.

    Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . : .

    [doi:10.1210/clinem/dgaf634]

  • Araujo-Castro M, Menéndez Torre E, Aida CL, García-Centeno R, González L, Idrobo C, Achote E, Irigaray Echarri A, Rodríguez-Argulló MDM, Paja M, Guerrero-Pérez F, Castaño JP, Dolores Ollero García M, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabeu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Martín-Rojas P, Recio-Córdova JM, Aulinas A, Asla Roca Q, Aviles MD, López Mezquita E, Fernández Argüeso M, González Molero I, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.

    Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(12): 3391-3399. Nº de citas: 6

    [doi:10.1210/clinem/dgaf252]

  • Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, Garcia-Carbonero R, Teulé A, Custodio A, Jimenez-Fonseca P, Lopez C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, Garcia-Alvarez A, Alonso-Gordoa T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E.

    Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

    CLINICAL CANCER RESEARCH . 31(22): 4655-4663. Nº de citas: 1

    [doi:10.1158/1078-0432.CCR-25-2143]

  • Martinez-Jañez N, García-Saenz JÁ, Pernas S, Bermejo B, Morales S, Guerra J, Silva J, Manso L, Ciruelos E, Tolosa P, Sánchez-Bayona R, Alva M, Calabuig-Fariñas S, Gallach S, Muinelo-Romay L, Piñeiro-Yáñez E, Caleiras E, Bueno MJ, Mouron S, Quintela-Fandino M.

    Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

    npj Precision Oncology . 9(1): 343-343.

    [doi:10.1038/s41698-025-01106-1]

  • Carmona-Bayonas A, Álvarez Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez Trufero J, Febrero Sánchez B, Saiz López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P.

    Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(11): 3155-3167. Nº de citas: 2

    [doi:10.1210/clinem/dgaf082]

  • Smith M, Piulats J, Todenhöfer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Fléchon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N.

    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    LANCET ONCOLOGY . 26(11): 1489-1500.

    [doi:10.1016/S1470-2045(25)00475-9]